Drugs / Mitiglinide
Mitiglinide
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07444424 | Mar → Jul 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01403818 | Jun → Aug 2011 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01443221 | Dec 2010 → Jan 2011 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01422590 | May 2010 → Apr 2011 | type 2 diabetes mellitus | Samsung Medical Center | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00519142 | Aug 2007 → Oct 2008 | type 2 diabetes mellitus | Elixir Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01333592 | ? → Aug 2012 | type 2 diabetes mellitus | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 45 trials · 2 met primary | ||||||
| Phase 4 | NCT02143765 | May 2014 → Dec 2015 | type 2 diabetes mellitus | Zhongda Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04349696 | Feb 2014 → Apr 2018 | liver disorder, type 2 diabetes mellitus | Orient Europharma Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00663884 | Feb 2008 → Jul 2009 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | Met primary |
| Phase 4 | NCT00369148 | Jul 2004 → Mar 2006 | type 2 diabetes mellitus | Keio University | Completed | No outcome recorded |
| Phase 4 | NCT02154347 | ? → Jul 2016 | type 2 diabetes mellitus | Kissei Pharmaceutical Co., Ltd. | Completed | Met primary |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT01456130 Background | Nov 2011 → Mar 2013 | diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01037842 Comparator | Aug 2006 → Mar 2008 | type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00461617 Comparator | Aug 2006 → Jul 2007 | diabetes mellitus | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02503943 Background | May 2015 → Sep 2016 | hypertensive disorder, obesity disorder, type 2 diabetes mellitus | Third Affiliated Hospital of Third Military Medical University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mitiglinide | “Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet” NCT01456130 ↗ |
| Known as | KAD-1229 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01333592 ↗ |
| Known as | Mitiglinide calcium hydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01403818 ↗ |
| Action | Inhibit | “the inhibitory effect of mitiglinide on the ATP-sensitive potassium (KATP) channel current through binding to sulfonylurea receptor in pancreatic cells.” NCT04349696 ↗ |
| Modality | Small molecule | “Mitiglinide, a benzylsuccinic acid derivative” NCT02143765 ↗ |
| Route | Oral | “Single oral administration of mitiglinide 10 mg” NCT01422590 ↗ |